Alto Neuroscience, Inc. (ANRO)Healthcare | Biotechnology | Mountain View, United States | NYSE
28.03 USD
+1.55
(5.853%)
⇧
(July 13, 2026, 4 p.m.
EDT)
After hours: 28.85 +0.82 (2.925%) ⇧ (July 13, 2026, 7:58 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 2:50 a.m. EDT
The investment case for Alto Neuroscience is currently broken by a catastrophic multi-year price collapse and deteriorating fundamentals. Despite a 'strong buy' analyst recommendation and a target price implying significant upside, the stock has lost over 80% of its value in the last year, a signal that the market has thoroughly reassessed the business quality and stripped away any prior premium. The company is burning cash with negative free cash flow and negative returns on equity, and there is no dividend to provide income or a floor. While the biotech sector often rewards catalysts, the current trajectory suggests the market is pricing in a failure of the current pipeline or execution. The options market confirms this pessimism, with traders aggressively buying cheap insurance against further drops rather than betting on a recovery. Until the company demonstrates a sustained turnaround in revenue growth or a definitive path to profitability that justifies the massive valuation gap, this remains a speculative trap for capital preservation. |
| Model | MAE |
|---|---|
| MSTL_55 ✓ | 0.084360 |
| AutoTheta | 0.117326 |
| AutoETS | 0.117352 |
| MSTL | 0.123252 |
| MSTL_55_102 | 0.153629 |
| MSTL_102 | 0.179799 |
| AutoARIMA | 0.388260 |
Forecast horizon: 60 days | Selected: MSTL_55
| Forecast Reliability | |
|---|---|
| Score | 28% |
| H-stat | 1.22 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.012 |
| Excess Kurtosis | 0.65 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 9.539 |
| Market Cap | 983,683,136 |
| Forward P/E | -8.16 |
| Beta | 1.07 |
| Website | https://www.altoneuroscience.com |
As of July 11, 2026, 2:50 a.m. EDT: Speculators are heavily positioned for downside protection with deep out-of-the-money puts showing massive open interest relative to volume, while call activity is sparse and concentrated at lower strikes. The implied volatility skew is extreme, with deep puts trading at significantly higher IV than calls, indicating a market consensus of high probability for further decline rather than a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | 8.880597 |
| Address1 | 650 Castro Street |
| Address2 | Suite 450 |
| All Time High | 28.441 |
| All Time Low | 1.6 |
| Ask | 28.97 |
| Ask Size | 200 |
| Average Daily Volume10 Day | 955,230 |
| Average Daily Volume3 Month | 434,752 |
| Average Volume | 434,752 |
| Average Volume10Days | 955,230 |
| Beta | 1.066 |
| Bid | 28.4 |
| Bid Size | 400 |
| Book Value | 6.943 |
| City | Mountain View |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 28.03 |
| Current Ratio | 20.52 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 28.4 |
| Day Low | 25.5 |
| Debt To Equity | 9.539 |
| Display Name | Alto Neuroscience |
| Earnings Timestamp | 1,778,675,400 |
| Earnings Timestamp End | 1,786,537,800 |
| Earnings Timestamp Start | 1,786,537,800 |
| Ebitda | -77,152,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -9.632 |
| Enterprise Value | 743,136,128 |
| Eps Current Year | -3.145 |
| Eps Forward | -3.43333 |
| Eps Trailing Twelve Months | -2.43 |
| Esg Populated | 0 |
| Exchange | NYQ |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 22.9954 |
| Fifty Day Average Change | 5.034601 |
| Fifty Day Average Change Percent | 0.2189395 |
| Fifty Two Week Change Percent | 888.0597 |
| Fifty Two Week High | 28.441 |
| Fifty Two Week High Change | -0.4109993 |
| Fifty Two Week High Change Percent | -0.014450944 |
| Fifty Two Week Low | 2.53 |
| Fifty Two Week Low Change | 25.5 |
| Fifty Two Week Low Change Percent | 10.079052 |
| Fifty Two Week Range | 2.53 - 28.441 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,706,884,200,000 |
| Float Shares | 23,659,282 |
| Forward Eps | -3.43333 |
| Forward P E | -8.164085 |
| Free Cashflow | -40,370,248 |
| Full Exchange Name | NYSE |
| Full Time Employees | 68 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.04552 |
| Held Percent Institutions | 0.82093 |
| Implied Shares Outstanding | 35,093,940 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California. |
| Market | us_market |
| Market Cap | 983,683,136 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_1675972978 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -74,306,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 929,287,531 |
| Number Of Analyst Opinions | 11 |
| Open | 26.45 |
| Operating Cashflow | -62,304,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 650 200 0412 |
| Post Market Change | 0.8199997 |
| Post Market Change Percent | 2.9254358 |
| Post Market Price | 28.85 |
| Post Market Time | 1,783,987,137 |
| Previous Close | 26.48 |
| Price Eps Current Year | -8.9125595 |
| Price Hint | 2 |
| Price To Book | 4.03716 |
| Profit Margins | 0.0 |
| Quick Ratio | 20.111 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 1.55 |
| Regular Market Change Percent | 5.85348 |
| Regular Market Day High | 28.4 |
| Regular Market Day Low | 25.5 |
| Regular Market Day Range | 25.5 - 28.4 |
| Regular Market Open | 26.45 |
| Regular Market Previous Close | 26.48 |
| Regular Market Price | 28.03 |
| Regular Market Time | 1,783,972,802 |
| Regular Market Volume | 2,079,405 |
| Return On Assets | -0.21706 |
| Return On Equity | -0.38856 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 35,093,940 |
| Shares Percent Shares Out | 0.0687 |
| Shares Short | 2,410,038 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 1,692,318 |
| Short Name | Alto Neuroscience, Inc. |
| Short Percent Of Float | 0.082100004 |
| Short Ratio | 4.16 |
| Source Interval | 15 |
| State | CA |
| Symbol | ANRO |
| Target High Price | 50.0 |
| Target Low Price | 24.0 |
| Target Mean Price | 35.13 |
| Target Median Price | 35.0 |
| Total Cash | 263,762,000 |
| Total Cash Per Share | 7.516 |
| Total Debt | 23,215,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.43 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 17.8788 |
| Two Hundred Day Average Change | 10.151201 |
| Two Hundred Day Average Change Percent | 0.5677787 |
| Type Disp | Equity |
| Volume | 2,079,405 |
| Website | https://www.altoneuroscience.com |
| Zip | 94,041 |